Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855559 | 1.00 | HCRTR1 (0.44) | HCRTR1HCRTR2SSTR4PDE10AFFAR4 | |
| SCHEMBL30689342 | 0.81 | HCRTR1 (0.46) | HCRTR1HCRTR2SSTR4PDE10ASSTR1 | |
| SCHEMBL21855680 | 0.80 | HCRTR1 (0.43) | HCRTR1HCRTR2SSTR4PDE10ASSTR1 | |
| SCHEMBL21855682 | 0.80 | HCRTR1 (0.43) | HCRTR1HCRTR2SSTR4PDE10ASSTR1 | |
| SCHEMBL30689324 | 0.78 | HCRTR1 (0.47) | HCRTR1HCRTR2SSTR4PDE10AFFAR4 | |
| SCHEMBL14127724 | 0.78 | CYP19A1 (0.46) | — | |
| SCHEMBL21939482 | 0.78 | PDE10A (0.42) | HCRTR1HCRTR2SSTR4PDE10ASSTR1 | |
| SCHEMBL14235504 | 0.78 | CYP19A1 (0.46) | — | |
| SCHEMBL15696551 | 0.77 | HCRTR1 (0.46) | HCRTR1HCRTR2PDE10AAVPR1A | |
| SCHEMBL15800230 | 0.77 | HCRTR1 (0.46) | HCRTR1HCRTR2PDE10AAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867232-B1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12152019-B2 | Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2020081381-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152019-B2 | Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, AADAC | HCRTR1 665/4885HCRTR2 521/4885SSTR4 3052/4885 |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, AADAC | HCRTR1 573/4885HCRTR2 414/4885SSTR4 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.